European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for appendiceal neuroendocrine tumours (aNET)

Translate
Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 34.3K other subscribers

Ronny Allan

Ronny Allan is a 3 x award-winning accredited patient leader advocating internationally for Neuroendocrine Cancer and all other cancer patients generally. Check out his Social Media accounts including Facebook, BlueSky, WhatsApp, Instagram and and X.

Appendiceal neuroendocrine tumours (aNET) account for 50%–77% of all appendiceal neoplasms and are mostly identified incidentally following appendicectomy for acute appendicitis or after a laparotomy performed for unrelated reasons. In the great majority, aNET are low grade (>80% grade 1 (G1)) and very rarely, if ever, are associated with a secretory syndrome. 

This post is part of my ENETS Guideline series and supplements my Spotlight series article which can be found by clicking here.

TABLE 1. Nine clinical questions for aNET scenarios.

Q1 – What is the current incidence of aNET (G1-3)?
Q2 – Which are the pathological parameters that need to be provided for further decision-making?
Q3 – How common are LN and distant metastases and carcinoid syndrome (CS) in appendiceal NET? Is LN status an acceptable surrogate of OS?
Q4 – Is there any indication for biochemical and/or imaging modalities to be utilised for tumour staging following appendicectomy?
Q5 – Is there any indication for biochemical and/or imaging modalities to be utilised for tumour staging following appendicectomy?
Q6 – When completion oncological surgery is recommended, is RHC always required or could ileocaecal resection be sufficient, and what is the impact of these
Q7 – Is there any need for adjuvant therapy in patients with aNET without distant metastases?
Q8 – How should advanced disease be managed?
Q9 – What is the recommended follow-up protocol after RHC in patients with or without LN+ ? How is follow-up in aNET justified?

Now read the reference material below including where applicable to the 9 questions above.

Reference

Click on the blue link below to read the discussion and the recommendations for each of those questions. 

European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for appendiceal neuroendocrine tumours (aNET)

Gregory Kaltsas, Thomas Walter, Ulrich Knigge, Christos Toumpanakis, Ana P. Santos, Nehara Begum, Ulrich F. Pape, Marco Volante, Andrea Frilling, Anne Couvelard

First published: 16 August 2023

https://doi.org/10.1111/jne.13332

More Guidelines

Read guidelines published so far - click picture to browse

Disclaimer

I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me. 

Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional. Some content may be generated by AI which can sometimes be misinterpreted.  Please check any references attached.    

Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.

Click here and answer all questions to join my private Facebook group
Top 10 Posts & Pages in the last 48 hours (auto updates) (Click the titles to read them)
Facebook Twitter WordPress Instagram

Thanks for reading.

Ronny

Blog Facebook. Like this page please.

Personal Facebook. Like this page please.

Awareness Facebook Like this page please.

Follow me on X (formerly twitter)

Check out my online presentations

Check out my WEGO Health Awards

Check out my Glossary of Terms – click here

patients included

Please Share this post for Neuroendocrine Cancer awareness and to help another patient

 
 
 
Facebook
X
Pinterest
WhatsApp
Email

16 years since diagnosis, I’m still here

July 26, 2026 7 Comments

I finally made 16 years since I was diagnosed on 26th July 2010.  A milestone I was not certain at the time I would reach.  However, as things progressed, as treatment was administered, and as I got used to living with Neuroendocrine Cancer, I eventually became more confident this was a possibility with the help […]

Read More »
Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 34.3K other subscribers
Buy me a cup of tea or two

Buy me a cup of tea or two? Change the number below to increment. i.e insert 2 = £8, 3 = £12, etc

Overheads to run this site, e.g. software packages, domain registration fees, software tools, misc items. Donate £4 or more so I have the fuel to keep on providing great content!

£4.00

Discover more from Ronny Allan - Living with Neuroendocrine Cancer

Subscribe to get the latest posts sent to your email.

Discover more from Ronny Allan - Living with Neuroendocrine Cancer

Subscribe now to keep reading and get access to the full archive.

Continue reading

Our website use cookies to improve and personalize your experience and to display advertisements(if any). Our website may also include cookies from third parties like Google Adsense, Google Analytics, Youtube. By using the website, you consent to the use of cookies. We have updated our Privacy Policy. Please click on the button to check our Privacy Policy.
Ok, I Agree